Search

Your search keyword '"Budaj, Andrzej"' showing total 1,035 results
Start Over Author "Budaj, Andrzej"
1,035 results on '"Budaj, Andrzej"'

101. The efficacy of ticagrelor is maintained in women with acute coronary syndromes participating in the prospective, randomized, PLATelet inhibition and patient Outcomes (PLATO) trial

Author

Husted, Steen, James, Stefan K., Bach, Richard G., Becker, Richard C., Budaj, Andrzej, Heras, Magda, Himmelmann, Anders, Horrow, Jay, Katus, Hugo A., Lassila, Riita, Morais, Joao, Nicolau, José C., Steg, Ph. Gabriel, Storey, Robert F., Wojdyla, Daniel, and Wallentin, Lars

Published
2014
Full Text
View/download PDF

103. Impact of Diabetes Mellitus and Chronic Kidney Disease on Cardiovascular Outcomes and Platelet P2Y 12 Receptor Antagonist Effects in Patients With Acute Coronary Syndromes: Insights From the PLATO Trial

Author

Franchi, Francesco, James, Stefan, Ghukasyan, Tatevik, Budaj, Andrzej J., Cornel, Jan H., Katus, Hugo A., Keltai, Matyas, Kontny, Frederic, Lewis, Basil S., Storey, Robert F., Himmelmann, Anders, Wallentin, Lars, Angiolillo, Dominick J., Parkhomenko, Alexander Nikolaevich, Oto, Ali, Skene, Allan, Budaj, Andrzej, Freij, Anneli, Santoso, Anwar, Armando, A, Meier, Bernhard, Yu, Cheuk Man, Cannon, Christopher P., Zambahari, Dato Seri Robaayah, Wu, Delon Wu, Ardissino, Diego, Raev, Dimitar, Kremastinos, Dimitrios, Weaver, Douglas, Paolasso, Ernesto, Giannitsis, Evangelos, Verheugt, Freek, Maurer, Gerald, Katus, Hugo, Emanuelsson, Hakan, Horrow, Jay, Bassand, Jean-Pierre, Spinar, Jindrich, Morais, Joao, Lopez Sendon, Jose, Nicolau, Jose, Seung, Ki-Bae, Teik, Lim Soo, Heras, Magda, Claeys, Marc J., Sabatine, Marc, Vintila, Marius, Ruda, Mikhail, Thorsen, Mona, Kleiman, Neil, Babilonia, Noe, Commerford, Patrick, Gurbel, Paul, Aylward, Phil, Steg, Philippe Gabriel, Theroux, Pierre, Sritara, Piyamitr, Pais, Prem, Becker, Richard, Lassila, Riitta, Harrington, Robert A., Gao, Runlin, Husted, Steen, Duris, Tibor, Chapichadze, Zaza, HUS Comprehensive Cancer Center, University Management, Department of Oncology, and PLATO Investigators

Subjects
Male, Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], Comorbidity, 030204 cardiovascular system & hematology, urologic and male genital diseases, FUNCTION PROFILES, RESPONSIVENESS, Electrocardiography, 0302 clinical medicine, Risk Factors, Coronary Heart Disease, ARTERY-DISEASE, Medicine, Cardiac and Cardiovascular Systems, 030212 general & internal medicine, Myocardial infarction, Stroke, Original Research, Kardiologi, Absolute risk reduction, Diabetes, Type 2, DUAL ANTIPLATELET THERAPY, Middle Aged, Prognosis, Clopidogrel, female genital diseases and pregnancy complications, 3. Good health, Survival Rate, diabetes mellitus, Female, Cardiology and Cardiovascular Medicine, Ticagrelor, medicine.drug, Platelets, RENAL-FUNCTION, medicine.medical_specialty, Acute coronary syndrome, ANTITHROMBOTIC THERAPY, INHIBITION, acute coronary syndrome, ticagrelor, 03 medical and health sciences, Internal medicine, Diabetes mellitus, Humans, Renal Insufficiency, Chronic, Aged, Retrospective Studies, Pharmacology, clopidogrel, Dose-Response Relationship, Drug, business.industry, Thrombosis, medicine.disease, United States, REACTIVITY, 3121 General medicine, internal medicine and other clinical medicine, Purinergic P2Y Receptor Antagonists, Human medicine, business, Acute Coronary Syndromes, Platelet Aggregation Inhibitors, chronic kidney disease, Follow-Up Studies, Kidney disease
Abstract

Background There are limited data on how the combination of diabetes mellitus ( DM ) and chronic kidney disease ( CKD ) affects cardiovascular outcomes as well as response to different P2Y 12 receptor antagonists, which represented the aim of the present investigation. Methods and Results In this post hoc analysis of the PLATO (Platelet Inhibition and Patient Outcomes) trial, which randomized acute coronary syndrome patients to ticagrelor versus clopidogrel, patients (n=15 108) with available DM and CKD status were classified into 4 groups: DM +/ CKD + (n=1058), DM +/ CKD − (n=2748), DM −/ CKD + (n=2160), and DM −/ CKD − (n=9142). The primary efficacy end point was a composite of cardiovascular death, myocardial infarction, or stroke at 12 months. The primary safety end point was PLATO major bleeding. DM +/ CKD + patients had a higher incidence of the primary end point compared with DM −/ CKD − patients (23.3% versus 7.1%; adjusted hazard ratio 2.22; 95% CI 1.88–2.63; P DM +/ CKD − and DM −/ CKD + had an intermediate risk profile. The same trend was shown for the individual components of the primary end point and for major bleeding. Compared with clopidogrel, ticagrelor reduced the incidence of the primary end point consistently across subgroups ( P ‐interaction=0.264), but with an increased absolute risk reduction in DM +/ CKD +. The effects on major bleeding were also consistent across subgroups ( P ‐interaction=0.288). Conclusions In acute coronary syndrome patients, a gradient of risk was observed according to the presence or absence of DM and CKD , with patients having both risk factors at the highest risk. Although the ischemic benefit of ticagrelor over clopidogrel was consistent in all subgroups, the absolute risk reduction was greatest in patients with both DM and CKD . Clinical Trial Registration URL : http://www.clinicatrials.gov . Unique identifier: NCT 00391872.

Published
2019

105. Risk markers of incident atrial fibrillation in patients with coronary heart disease

Author

Tomasdottir, Maria, primary, Held, Claes, additional, Hadziosmanovic, Nermin, additional, Westerbergh, Johan, additional, Lindbäck, Johan, additional, Aylward, Philip E., additional, Budaj, Andrzej, additional, Cannon, Christopher P., additional, Engdahl, Johan, additional, Granger, Christopher B., additional, Koenig, Wolfgang, additional, Manolis, Athanasios J., additional, Oldgren, Jonas, additional, Stewart, Ralph A.H., additional, Svennberg, Emma, additional, Vinereanu, Dragos, additional, White, Harvey D., additional, Siegbahn, Agneta, additional, Wallentin, Lars, additional, and Hijazi, Ziad, additional

Published
2021
Full Text
View/download PDF

109. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006

Author

Fox, Keith A.A., Steg, Philippe Gabriel, Eagle, Kim A., Goodman, Shaun C., Anderson, Federick A., Granger, Christopher B., Flather, Marcus D., Budaj, Andrzej, Quill, Ann, and Gore, Joel M.

Subjects
Heart failure -- Risk factors, Heart failure -- Research, Coronary heart disease -- Care and treatment, Coronary heart disease -- Research, Cardiac patients -- Patient outcomes
Abstract

The rates of deaths and heart failure in patients with ST-segment elevation and non-ST-segment elevation acute coronary syndromes from 1999 to 2006 have decreased. This is mainly attributed to improved hospital management of patients and increase in interventional treatments.

Published
2007

110. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: The MERLIN-TIMI 36 randomized trial

Author

Morrow, David A., Scirica, Benjamin M., Karwatowska-Prokopczuk, Ewa, Murphy, Sabina A., Budaj, Andrzej, Varshavsky, Sergei, Wolff, Andrew A., Skene, Allan, McCabe, Carolyn H, and Braunwald, Eugene

Subjects
Ranolazine -- Dosage and administration, Ranolazine -- Research, Coronary heart disease -- Drug therapy
Abstract

The Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes (MERLIN)-TIMI 36 trial is used to determine the efficacy and safety of ranolazine during long-term treatment of patients with non-ST-elevation acute coronary syndromes (ACS). The results have shown that the addition of ranolazine to standard treatment for ACS is not effective for reducing major cardiovascular events and did not adversely affect the risk of all-cause death or symptomatic documented arrhythmia.

Published
2007

111. In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular events

Author

White, Harvey D., Stewart, Ralph A. H., Dolby, Anthony J., Stebbins, Amanda, Cannon, Christopher P., Budaj, Andrzej, Linhart, Ales, Pais, Prem, Diaz, Rafael, Steg, Philippe Gabriel, Krug-Gourley, Sue, Granger, Christopher B., Hochman, Judith S., Koenig, Wolfgang, Harrington, Robert A., Held, Claes, Wallentin, Lars, White, Harvey D., Stewart, Ralph A. H., Dolby, Anthony J., Stebbins, Amanda, Cannon, Christopher P., Budaj, Andrzej, Linhart, Ales, Pais, Prem, Diaz, Rafael, Steg, Philippe Gabriel, Krug-Gourley, Sue, Granger, Christopher B., Hochman, Judith S., Koenig, Wolfgang, Harrington, Robert A., Held, Claes, and Wallentin, Lars

Abstract

Background In patients with stable coronary heart disease, it is not known whether achievement of standard of care (SOC) targets in addition to evidence-based medicine (EBM) is associated with lower major adverse cardiovascular events (MACE): cardiovascular death, myocardial infarction, and stroke. Methods EBM use was recommended in the STabilisation of Atherosclerotic plaque By Initiation of darapLadIb TherapY trial. SOC targets were blood pressure (BP) <140/90 mm Hg and low-density lipoprotein-cholesterol (LDL-C) <100 mg/dL and <70 mg/dL. In patients with diabetes, glycosylated hemoglobin A1c (HbA1c) < 7% and BP of <130/80 mm Hg were recommended. Feedback to investigators about rates of EBM and SOC was provided regularly. Results In 13,623 patients, 1-year landmark analysis assessed the association between EBM, SOC targets, and MACE during follow-up of 2.7 years (median) after adjustment in a Cox proportional hazards model. At 1 year, aspirin was prescribed in 92.5% of patients, statins in 97.2%, β-blockers in 79.0%, and angiotensin-converting enzyme inhibitors/angiotensin-II receptor blockers in 76.9%. MACE was lower with LDL-C < 100 mg/dL (70-99 mg/dL) compared with LDL-C ≥ 100 mg/dL (hazard ratio [HR] 0.694, 95% CI 0.594-0.811) and lower with LDL-C < 70 mg/dL compared with LDL-C < 100 mg/dL (70-99 mg/dL) (HR 0.834, 95% CI 0.708-0.983). MACE was lower with HbA1c < 7% compared with HbA1c ≥ 7% (HR 0.705, 95% CI 0.573-0.866). There was no effect of BP targets on MACE. Conclusions MACE was lower with LDL-C < 100 mg/dL (70-99 mg/dL) and even lower with LDL-C < 70 mg/dL. MACE in patients with diabetes was lower with HbA1c < 7%. Achievement of targets is associated with improved patient outcomes.

Published
2020
Full Text
View/download PDF

112. Prolonged antithrombotic therapy in patients after acute coronary syndrome : A critical appraisal of current European Society of Cardiology guidelines

Author

Kubica, Jacek, Adamski, Piotr, Niezgoda, Piotr, Alexopoulos, Dimitrios, Badariene, Jolita, Budaj, Andrzej, Buszko, Katarzyna, Dudek, Dariusz, Fabiszak, Tomasz, Gasior, Mariusz, Gil, Robert, Gorog, Diana A., Grajek, Stefan, Gurbel, Paul A., Gruchala, Marcin, Jaguszewski, Milosz J., James, Stefan, Jeong, Young-Hoon, Jilma, Bernd, Kasprzak, Jaroslaw D., Kleinrok, Andrzej, Kubica, Aldona, Kuliczkowski, Wiktor, Legutko, Jacek, Lesiak, Maciej, Siller-Matula, Jolanta M., Nadolny, Klaudiusz, Pstragowski, Krzysztof, Di Somma, Salvatore, Specchia, Giuseppe, Stepinska, Janina, Tantry, Udaya S., Tycinska, Agnieszka, Verdoia, Monica, Wojakowski, Wojciech, Navarese, Eliano P., Kubica, Jacek, Adamski, Piotr, Niezgoda, Piotr, Alexopoulos, Dimitrios, Badariene, Jolita, Budaj, Andrzej, Buszko, Katarzyna, Dudek, Dariusz, Fabiszak, Tomasz, Gasior, Mariusz, Gil, Robert, Gorog, Diana A., Grajek, Stefan, Gurbel, Paul A., Gruchala, Marcin, Jaguszewski, Milosz J., James, Stefan, Jeong, Young-Hoon, Jilma, Bernd, Kasprzak, Jaroslaw D., Kleinrok, Andrzej, Kubica, Aldona, Kuliczkowski, Wiktor, Legutko, Jacek, Lesiak, Maciej, Siller-Matula, Jolanta M., Nadolny, Klaudiusz, Pstragowski, Krzysztof, Di Somma, Salvatore, Specchia, Giuseppe, Stepinska, Janina, Tantry, Udaya S., Tycinska, Agnieszka, Verdoia, Monica, Wojakowski, Wojciech, and Navarese, Eliano P.

Abstract

The increased risk of non-cardiovascular death in patients receiving clopidogrel or prasugrel in comparison with the placebo group in the Dual Antiplatelet Therapy (DAPT) trial in contrast to the decreased risk of cardiovascular death and all-cause death seen in patients treated with low-dose ticagrelor in the EU label population of the PEGASUS-TIMI 54 trial, resulted in inclusion in the 2020 ESC NSTE-ACS guidelines the recommendation for use of clopidogrel or prasugrel only if the patient is not eligible for treatment with ticagrelor. The prevalence of the primary outcome composed of cardiovascular death, stroke, or myocardial infarction was lower in the low-dose rivaroxaban and acetylsalicylic acid (ASA) group than in the ASA-alone group in the COMPASS trial. Moreover, all-cause mortality and cardiovascular mortality rates were lower in the rivaroxaban-plus-ASA group. Comparison of the PEGASUS-TIMI 54 and COMPASS trial patient characteristics clearly shows that each of these treatment strategies should be addressed at different groups of patients. A greater benefit in post-acute coronary syndrome (ACS) patients with a high risk of ischemic events and without high bleeding risk may be expected with ASA and ticagrelor 60 mg b.i.d. when the therapy is continued without interruption or with short interruption only after ACS. On the other hand, ASA and rivaroxaban 2.5 mg b.i.d. seems to be a better option when indications for dual antithrombotic therapy (DATT) appear after a longer time from ACS (more than 2 years) and/or from cessation of DAPT (more than 1 year) and in patients with multiple vascular bed atherosclerosis. Thus, both options of DATTs complement each other rather than compete, as can be presumed from the recommendations. However, a direct comparison between these strategies should be tested in future clinical trials.

Published
2020
Full Text
View/download PDF

115. Association of peripheral artery disease with treatment and outcomes in acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE)

Author

Froehlich, James B., Mukherjee, Debabrata, Avezum, Alvaro, Budaj, Andrzej, Kline-Rogers, Eva M., Lopez-Sendon, Jose, Allegrone, Jeanna, Eagle, Kim A., Mehta, Rajendra H., and Goldberg, Robert J.

Subjects
Peripheral vascular diseases -- Care and treatment, Peripheral vascular diseases -- Research, Therapeutics -- Patient outcomes, Therapeutics -- Research, Coronary heart disease -- Care and treatment, Coronary heart disease -- Prevention, Coronary heart disease -- Research, Homeopathy -- Materia medica and therapeutics, Homeopathy -- Patient outcomes, Homeopathy -- Research, Health
Published
2006

116. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction

Author

Antman, Elliott M., Morrow, David A., McCabe, Carolyn H., Murphy, Sabina A., Ruda, Mikhail, Sadowski, Zygmunt, Budaj, Andrzej, Lopez-Sendon, Jose L., Guneri, Sema, Jiang, Frank, White, Harvey D., Fox, Keith A.A., and Barunwald, Eugene

Subjects
Heparin -- Health aspects, Heparin -- Comparative analysis, Fibrinolysis -- Care and treatment, Heart attack -- Health aspects, Enoxaparin -- Comparative analysis, Enoxaparin -- Health aspects
Abstract

Unfractioned heparin is often used as adjunctive therapy with fibrinolysis in patients with ST-elevation myocardinal infarction thus a comparative study is conducted with a low-molecular-weight heparin, enoxaparin with unfractionated heparin. It is observed that in patients receiving fibrinolysis for ST-elevation myocardial infarction, treatment with enoxaparin throughout the index hospitalization is superior to treatment with unfractionated heparin for 48hours but is associated with an increase in major bleeding episodes.

Published
2006

117. The diagnostic and prognostic impact of the redefinition of acute myocardial infarction: lessons from the Global Registry of Acute Coronary Events (GRACE)

Author

Goodman, Shaun G., Steg, Philippe Gabriel, Eagle, Kim A., Fox, Keith A.A., Lopez-Sendon, Jose, Montalescot, Gilles, Budaj, Andrzej, Kennelly, Brian M., Gore, Joel M., Allegrone, Jeanna, Granger, Christopher B., and Gurfinkel, Enrique P.

Subjects
Heart attack -- Patient outcomes, Heart attack -- Research, Cardiac patients -- Prognosis, Cardiac patients -- Research, Health
Published
2006

118. Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long‐Term Ticagrelor in Stable Patients With Prior Myocardial Infarction

Author

Magnani, Giulia, primary, Ardissino, Diego, additional, Im, KyungAh, additional, Budaj, Andrzej, additional, Storey, Robert F., additional, Steg, P. Gabriel, additional, Bhatt, Deepak L., additional, Cohen, Marc, additional, Oude Ophius, Ton, additional, Goudev, Assen, additional, Parkhomenko, Alexander, additional, Kamensky, Gabriel, additional, Angiolillo, Dominick J., additional, López‐Sendón, José, additional, Johanson, Per, additional, Braunwald, Eugene, additional, Sabatine, Marc S., additional, and Bonaca, Marc P., additional

Published
2021
Full Text
View/download PDF

120. Antiplatelet therapy in patients with myocardial infarction without obstructive coronary artery disease

Author

Bossard, Matthias, primary, Gao, Peggy, additional, Boden, William, additional, Steg, Gabriel, additional, Tanguay, Jean-Francois, additional, Joyner, Cam, additional, Granger, Christopher B, additional, Kastrati, Adnan, additional, Faxon, David, additional, Budaj, Andrzej, additional, Pais, Prem, additional, Di Pasquale, Giuseppe, additional, Valentin, Vicent, additional, Flather, Marcus, additional, Moccetti, Tiziano, additional, Yusuf, Salim, additional, and Mehta, Shamir R, additional

Published
2021
Full Text
View/download PDF

122. Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study

Author

Lewis, Basil S., Mehta, Shamir R., Fox, Keith A.A., Halon, David A., Zhao, Feng, Peters, Ron J.G., Keltai, Matyas, Budaj, Andrzej, and Yusuf, Salim

Subjects
Coronary heart disease -- Drug therapy, Drug therapy, Combination -- Research, Transluminal angioplasty -- Research, Blood platelets -- Aggregation, Blood platelets -- Research, Health
Published
2005

123. Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines

Author

Kubica, Jacek, primary, Adamski, Piotr, additional, Niezgoda, Piotr, additional, Alexopoulos, Dimitrios, additional, Badarienė, Jolita, additional, Budaj, Andrzej, additional, Buszko, Katarzyna, additional, Dudek, Dariusz, additional, Fabiszak, Tomasz, additional, Gąsior, Mariusz, additional, Gil, Robert, additional, Gorog, Diana A., additional, Grajek, Stefan, additional, Gurbel, Paul A., additional, Gruchała, Marcin, additional, Jaguszewski, Miłosz J., additional, James, Stefan, additional, Jeong, Young-Hoon, additional, Jilma, Bernd, additional, Kasprzak, Jarosław D., additional, Kleinrok, Andrzej, additional, Kubica, Aldona, additional, Kuliczkowski, Wiktor, additional, Legutko, Jacek, additional, Lesiak, Maciej, additional, Siller-Matula, Jolanta M., additional, Nadolny, Klaudiusz, additional, Pstrągowski, Krzysztof, additional, Di Somma, Salvatore, additional, Specchia, Giuseppe, additional, Stępińska, Janina, additional, Tantry, Udaya S., additional, Tycińska, Agnieszka, additional, Verdoia, Monica, additional, Wojakowski, Wojciech, additional, and Navarese, Eliano P., additional

Published
2020
Full Text
View/download PDF

124. Assessment of quality of care of patients with ST-segment elevation myocardial infarction

Author

Hudzik, Bartosz, primary, Budaj, Andrzej, additional, Gierlotka, Marek, additional, Witkowski, Adam, additional, Wojakowski, Wojciech, additional, Zdrojewski, Tomasz, additional, Gil, Robert, additional, Legutko, Jacek, additional, Bartuś, Stanisław, additional, Buszman, Paweł, additional, Dudek, Dariusz, additional, and Gąsior, Mariusz, additional

Published
2020
Full Text
View/download PDF

126. A validated prediction model for all forms of acute coronary syndrome

Author

Eagle, Kim A., Lim, Michael J., Dabbous, Omar H., Pieper, Karen S., Goldberg, Robert J., Werf, Frans Van de, Goodman, Shaun G., Granger, Christopher B., Steg, Gabriel P., Gore, Joel M., Budaj, Andrzej, Avezum, Alvaro, Flather, Marcus D., and Fox, Keith A.A.

Subjects
Coronary heart disease -- Care and treatment, Coronary heart disease -- Research
Abstract

A simple decision tool for bedside risk estimation of 6-month mortality in patients surviving admission for an acute coronary syndrome (ACS) is developed. The Global Registry of Acute Coronary Events (GRACE) 6-month postdischarge prediction model is a simple, robust tool for predicting mortality in patients with ACS applicable for clinical practice.

Published
2004

127. Elevated Leukocyte count and adverse hospital events in patients with acute coronary syndromes: Findings from the global registry of coronary events(GRACE)

Author

Furman, Mark I., Gore, Joel M., Anderson, Fredrick A., Budaj, Andrzej, Goodman, Shaun G., Avezum, Avaro, Lopez-Sendon, Jose, Klein, Werner, Mukherjee, Debabrata, Eagle, Kim A., Dabbous, Omar H., and Goldberg, Robert J.

Subjects
Cardiac patients -- Research, Coronary heart disease -- Research, Coronary heart disease -- Care and treatment, Leukocytes -- Research, Health
Published
2004

128. 2013 ESC guidelines on the management of stable coronary artery disease: The Task Force on the management of stable coronary artery disease of the European Society of Cardiology

Author

Montalescot, Gilles, Sechtem, Udo, Achenbach, Stephan, Andreotti, Felicita, Arden, Chris, Budaj, Andrzej, Bugiardini, Raffaele, Crea, Filippo, Cuisset, Thomas, Di Mario, Carlo, Ferreira, J. Rafael, Gersh, Bernard J., Gitt, Anselm K., Hulot, Jean-Sebastien, Marx, Nikolaus, Opie, Lionel H., Pfisterer, Matthias, Prescott, Eva, Ruschitzka, Frank, Sabaté, Manel, Senior, Roxy, Taggart, David Paul, van der Wall, Ernst E., Vrints, Christiaan J.M., Zamorano, Jose Luis, Achenbach, Stephan, Baumgartner, Helmut, Bax, Jeroen J., Bueno, Héctor, Dean, Veronica, Deaton, Christi, Erol, Cetin, Fagard, Robert, Ferrari, Roberto, Hasdai, David, Hoes, Arno W., Kirchhof, Paulus, Knuuti, Juhani, Kolh, Philippe, Lancellotti, Patrizio, Linhart, Ales, Nihoyannopoulos, Petros, Piepoli, Massimo F., Ponikowski, Piotr, Sirnes, Per Anton, Tamargo, Juan Luis, Tendera, Michal, Torbicki, Adam, Wijns, William, Windecker, Stephan, Knuuti, Juhani, Valgimigli, Marco, Bueno, Héctor, Claeys, Marc J., Donner-Banzhoff, Norbert, Erol, Cetin, Frank, Herbert, Funck-Brentano, Christian, Gaemperli, Oliver, Gonzalez-Juanatey, José R., Hamilos, Michalis, Hasdai, David, Husted, Steen, James, Stefan K., Kervinen, Kari, Kolh, Philippe, Kristensen, Steen Dalby, Lancellotti, Patrizio, Maggioni, Aldo Pietro, Piepoli, Massimo F., Pries, Axel R., Romeo, Francesco, Rydén, Lars, Simoons, Maarten L., Sirnes, Per Anton, Steg, Ph. Gabriel, Timmis, Adam, Wijns, William, Windecker, Stephan, Yildirir, Aylin, and Zamorano, Jose Luis

Published
2013
Full Text
View/download PDF

131. Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: Insights from the global registry of acute coronary events(GRACE)

Author

Budaj, Andrzej, Brieger, David, Steg, Gabriel, Goodman, Shaun G., Dabbous, Omar H., Fox, Keith A.A., Avezum, Alvaro, Cannon, Christopher P., Mazurek, Tomasz, Flather, Marcus D., and Werf, Frans Van de

Subjects
Blood platelets -- Aggregation, Blood platelets -- Research, Coronary heart disease -- Research, Coronary heart disease -- Care and treatment, Thrombolytic drugs -- Research, Health
Published
2003

132. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death)

Author

Zipes, Douglas P., Camm, A. John, Borggrefe, Martin, Buxton, Alfred E., Chaitman, Bernard, Fromer, Martin, Gregoratos, Gabriel, Klein, George, Myerburg, Robert J., Quinones, Miguel A., Roden, Dan M., Silka, Michael J., Tracy, Cynthia, Smith, Sidney C., Jr, Jacobs, Alice K., Adams, Cynthia D., Antman, Elliott M., Anderson, Jeffrey L., Hunt, Sharon A., Halperin, Jonathan L., Nishimura, Rick, Ornato, Joseph P., Page, Richard L., Riegel, Barbara, Priori, Silvia G., Moss, Arthur J., Blanc, Jean-Jacques, Budaj, Andrzej, Dean, Veronica, Deckers, Jaap W., Despres, Catherine, Dickstein, Kenneth, Lekakis, John, McGregor, Keith, Metra, Marco, Morais, Joao, Osterspey, Ady, Tamargo, Juan Luis, and Zamorano, José Luis

Published
2006
Full Text
View/download PDF

133. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death—Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death)

Author

Zipes, Douglas P., Camm, A. John, Borggrefe, Martin, Buxton, Alfred E., Chaitman, Bernard, Fromer, Martin, Gregoratos, Gabriel, Klein, George, Myerburg, Robert J., Quinones, Miguel A., Roden, Dan M., Silka, Michael J., Tracy, Cynthia, Smith, Sidney C., Jr, Jacobs, Alice K., Adams, Cynthia D., Anderson, Jeffrey L., Hunt, Sharon A., Halperin, Jonathan L., Nishimura, Rick, Ornato, Joseph P., Page, Richard L., Riegel, Barbara, Priori, Silvia G., Moss, Arthur J., Antman, Elliott M., Blanc, Jean-Jacques, Budaj, Andrzej, Dean, Veronica, Deckers, Jaap W., Despres, Catherine, Dickstein, Kenneth, Lekakis, John, McGregor, Keith, Metra, Marco, Morais, Joao, Osterspey, Ady, Tamargo, Juan Luis, and Zamorano, José Luis

Published
2006
Full Text
View/download PDF

134. Bleeding During Treatment With Aspirin Versus Apixaban in Patients With Atrial Fibrillation Unsuitable for Warfarin: The Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin k Antagonist Treatment (AVERROES) Trial

Author

Flaker, Greg C., Eikelboom, John W., Shestakovska, Olga, Connolly, Stuart J., Kaatz, Scott, Budaj, Andrzej, Husted, Steen, Yusuf, Salim, Lip, Gregory Y. H., and Hart, Robert G.

Published
2012
Full Text
View/download PDF

137. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC)

Author

Steg, Ph. Gabriel, James, Stefan K., Atar, Dan, Badano, Luigi P., Lundqvist, Carina Blomstrom, Borger, Michael A., Di Mario, Carlo, Dickstein, Kenneth, Ducrocq, Gregory, Fernandez-Aviles, Francisco, Gershlick, Anthony H., Giannuzzi, Pantaleo, Halvorsen, Sigrun, Huber, Kurt, Juni, Peter, Kastrati, Adnan, Knuuti, Juhani, Lenzen, Mattie J., Mahaffey, Kenneth W., Valgimigli, Marco, vanʼt Hof, Arnoud, Widimsky, Petr, Zahger, Doron, Bax, Jeroen J., Baumgartner, Helmut, Ceconi, Claudio, Dean, Veronica, Deaton, Christi, Fagard, Robert, Funck-Brentano, Christian, Hasdai, David, Hoes, Arno, Kirchhof, Paulus, Knuuti, Juhani, Kolh, Philippe, McDonagh, Theresa, Moulin, Cyril, Popescu, Bogdan A., Reiner, Željko, Sechtem, Udo, Sirnes, Per Anton, Tendera, Michal, Torbicki, Adam, Vahanian, Alec, Windecker, Stephan, Hasdai, David, Astin, Felicity, Åström-Olsson, Karin, Budaj, Andrzej, Clemmensen, Peter, Collet, Jean-Philippe, Fox, Keith A., Fuat, Ahmet, Gustiene, Olivija, Hamm, Christian W., Kala, Petr, Lancellotti, Patrizio, Maggioni, Aldo Pietro, Merkely, Béla, Neumann, Franz-Josef, Piepoli, Massimo F., Van de Werf, Frans, Verheugt, Freek, and Wallentin, Lars

Published
2012
Full Text
View/download PDF

139. Low-Dose Glucose-Insulin-Potassium Is Ineffective in Acute Myocardial Infarction: Results of a Randomized Multicenter Pol-GIK Trial

Author

Ceremużyński, Leszek, Budaj, Andrzej, Czepiel, Aleksandra, Burzykowski, Tomasz, Achremczyk, Piotr, Śmielak-Korombel, Wanda, Maciejewicz, Janusz, Dziubińska, Jadwiga, Nartowicz, Edmund, Kawka-Urbanek, Teresa, Piotrowski, Wieslaw, Hanzlik, Janusz, Cieśliński, Andrzej, Kawecka-Jaszcz, Kalina, Gessek, Jacek, and Wrabec, Krzysztof

Published
1999
Full Text
View/download PDF

140. Dronedarone in High-Risk Permanent Atrial Fibrillation

Author

Connolly, Stuart J., Camm, John A., Halperin, Jonathan L., Joyner, Campbell, Alings, Marco, Amerena, John, Atar, Dan, Avezum, Álvaro, Blomström, Per, Borggrefe, Martin, Budaj, Andrzej, Chen, Shih-Ann, Ching, Chi Keong, Commerford, Patrick, Dans, Antonio, Davy, Jean-Marc, Delacrétaz, Etienne, Di Pasquale, Giuseppe, Diaz, Rafael, Dorian, Paul, Flaker, Greg, Golitsyn, Sergey, Gonzalez-Hermosillo, Antonio, Granger, Christopher B., Heidbüchel, Hein, Kautzner, Josef, Kim, June Soo, Lanas, Fernando, Lewis, Basil S., Merino, Jose L., Morillo, Carlos, Murin, Jan, Narasimhan, Calambur, Paolasso, Ernesto, Parkhomenko, Alexander, Peters, Nicholas S., Sim, Kui-Hian, Stiles, Martin K., Tanomsup, Supachai, Toivonen, Lauri, Tomcsányi, János, Torp-Pedersen, Christian, Tse, Hung-Fat, Vardas, Panos, Vinereanu, Dragos, Xavier, Denis, Zhu, Jun, Zhu, Jun-Ren, Baret-Cormel, Lydie, Weinling, Estelle, Staiger, Christoph, Yusuf, Salim, Chrolavicius, Susan, Afzal, Rizwan, and Hohnloser, Stefan H.

Published
2011
Full Text
View/download PDF

143. Apixaban in Patients with Atrial Fibrillation

Author

Connolly, Stuart J., Eikelboom, John, Joyner, Campbell, Diener, Hans-Christoph, Hart, Robert, Golitsyn, Sergey, Flaker, Greg, Avezum, Alvaro, Hohnloser, Stefan H., Diaz, Rafael, Talajic, Mario, Zhu, Jun, Pais, Prem, Budaj, Andrzej, Parkhomenko, Alexander, Jansky, Petr, Commerford, Patrick, Tan, Ru San, Sim, Kui-Hian, Lewis, Basil S., Van Mieghem, Walter, Lip, Gregory Y.H., Kim, Jae Hyung, Lanas-Zanetti, Fernando, Gonzalez-Hermosillo, Antonio, Dans, Antonio L., Munawar, Muhammad, OʼDonnell, Martin, Lawrence, John, Lewis, Gayle, Afzal, Rizwan, and Yusuf, Salim

Published
2011

148. A multinational registry to study the characteristics and outcomes of heart failure patients: The global congestive heart failure (G-CHF) registry

Author

Joseph, Philip, primary, Dokainish, Hisham, additional, McCready, Tara, additional, Budaj, Andrzej, additional, Roy, Ambuj, additional, Ertl, Georg, additional, Gomez-Mesa, Juan Esteban, additional, Leong, Darryl, additional, Ezekowitz, Justin, additional, Hage, Camilla, additional, Lanas, Fernando, additional, Maggioni, Aldo P., additional, Sliwa, Karen, additional, Zhu, Jun, additional, Rouleau, Jean, additional, Balasubramanian, Kumar, additional, and Yusuf, Salim, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results